Cardlytics, Inc., a purchase intelligence platform that helps make marketing more relevant and measurable, announced the pricing of its initial public offering of 5,400,000 shares of common stock at a price to the public of $13.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Cardlytics. In addition, Cardlytics has granted the underwriters a 30-day option to purchase up to an additional 810,000 shares of common stock. Cardlytics’ common stock is expected to begin trading on the Nasdaq Global Market under the ticker symbol “CDLX” on February 9, 2018.  The offering is expected to close on February 13, 2018, subject to the satisfaction of customary closing conditions.

BofA Merrill Lynch and J.P. Morgan are acting as joint book-running managers and representatives of the underwriters for the offering. Wells Fargo Securities and SunTrust Robinson Humphrey are also acting as book-runners for the offering.  Raymond James and KeyBanc Capital Markets are acting as co-managers for the offering.